{
  "id": "56f7c44109dd18d46b000013",
  "type": "yesno",
  "question": "Is Kanzaki disease associated with deficiency in alpha-N-acetylgalactosaminidase?",
  "ideal_answer": "Yes, Kanzaki disease is attributable to a deficiency in alpha-N-acetylgalactosaminidase, which hydrolyzes GalNAcalpha1-O-Ser/Thr.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/11251574",
    "http://www.ncbi.nlm.nih.gov/pubmed/14685826",
    "http://www.ncbi.nlm.nih.gov/pubmed/19683538",
    "http://www.ncbi.nlm.nih.gov/pubmed/8577046",
    "http://www.ncbi.nlm.nih.gov/pubmed/15136691",
    "http://www.ncbi.nlm.nih.gov/pubmed/15619430"
  ],
  "snippets": [
    {
      "text": "Kanzaki disease (OMIM#104170) is attributable to a deficiency in alpha-N-acetylgalactosaminidase (alpha-NAGA; E.C.3.2.1.49), which hydrolyzes GalNAcalpha1-O-Ser/Thr. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15619430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Our findings suggest that the association of alpha-NAGA with its substrates is strongly affected by the amino acid substitution at R329 and that the association with GalNAcalpha1-O-Thr is more highly susceptible to structural changes. The residual mutant enzyme in R329W could not associate with GalNAcalpha1-O-Thr and GalNAcalpha1-O-Ser. However, the residual mutant enzyme in R329Q catalyzed GalNAcalpha1-O-Ser to some extent. Therefore, the urinary ratio of GalNAcalpha1-O-Ser:GalNAcalpha1-O-Thr was lower and the clinical phenotype was milder in the R329Q mutation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15619430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Kanzaki disease (OMIM#104170) is attributable to a deficiency in alpha-N-acetylgalactosaminidase (alpha-NAGA; E.C.3.2.1.49), which hydrolyzes GalNAcalpha1-O-Ser/Thr.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15619430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency (Schindler/Kanzaki disease) is a clinically and pathologically heterogeneous genetic disease with a wide spectrum including an early onset neuroaxonal dystrophy (Schindler disease) and late onset angiokeratoma corporis diffusum (Kanzaki disease).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14685826",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14685826",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We describe the neurologic findings in a patient with alpha-N-acetylgalactosaminidase deficiency (Kanzaki disease).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15136691",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Three dimensional structural studies of alpha-N-acetylgalactosaminidase (alpha-NAGA) in alpha-NAGA deficiency (Kanzaki disease): different gene mutations cause peculiar structural changes in alpha-NAGAs resulting in different substrate specificities and clinical phenotypes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15619430",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency is a rare hereditary lysosomal storage disease, and only three alpha-NAGA-deficient patients with angiokeratoma corporis diffusum (Kanzaki) have been described.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11251574",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Schindler disease and Kanzaki disease are caused by a deficient lysosomal enzyme, alpha-N-acetylgalactosaminidase (E.C.3.2.1.49).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8577046",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The 1.9 a structure of human alpha-N-acetylgalactosaminidase: The molecular basis of Schindler and Kanzaki diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19683538",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "These data suggest that a prototype of alpha-NAGA deficiency in Kanzaki disease and factors other than the defect of alpha-NAGA may contribute to severe neurological disorders, and Kanzaki disease is thought to be caused by a single enzyme deficiency.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14685826",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency (Schindler/Kanzaki disease) is a clinically and pathologically heterogeneous genetic disease with a wide spectrum including an early onset neuroaxonal dystrophy (Schindler disease) and late onset angiokeratoma corporis diffusum (Kanzaki disease). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14685826",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency is a rare hereditary lysosomal storage disease, and only three alpha-NAGA-deficient patients with angiokeratoma corporis diffusum (Kanzaki) have been described. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11251574",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Kanzaki disease (OMIM#104170) is attributable to a deficiency in alpha-N-acetylgalactosaminidase (alpha-NAGA; E.C.3.2.1.49), which hydrolyzes GalNAcalpha1-O-Ser/Thr. Missense mutations, R329W or R329Q were identified in two Japanese Kanzaki patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15619430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency (Schindler/Kanzaki disease) is a clinically and pathologically heterogeneous genetic disease with a wide spectrum including an early onset neuroaxonal dystrophy (Schindler disease) and late onset angiokeratoma corporis diffusum (Kanzaki disease).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14685826",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Kanzaki disease (OMIM#104170) is attributable to a deficiency in alpha-N-acetylgalactosaminidase (alpha-NAGA; E.C.3.2.1.49),",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15619430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Kanzaki disease (OMIM#104170) is attributable to a deficiency in alpha-N-acetylgalactosaminidase (alpha-NAGA; E.C.3.2.1.49), which hydrolyzes GalNAcalpha1-O-Ser/Thr.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15619430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency is a rare hereditary lysosomal storage disease, and only three alpha-NAGA-deficient patients with angiokeratoma corporis diffusum (Kanzaki) have been described.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11251574",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.uniprot.org/uniprot/NAGAB_CHICK",
    "http://www.uniprot.org/uniprot/NAGAB_BOSIN",
    "http://www.uniprot.org/uniprot/NAGAB_RAT",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048809",
    "http://www.uniprot.org/uniprot/G1092_BACFN",
    "http://www.uniprot.org/uniprot/GH109_ELIME",
    "http://www.uniprot.org/uniprot/GH109_SHEON",
    "http://www.uniprot.org/uniprot/NAGAB_HUMAN"
  ],
  "exact_answer": "Yes"
}